Full Press Release Details
BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union.
BIIB
BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
Key Takeaway: BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis